EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation

Monika Conchon, Sabri S Sanabani, Israel Bendit, Carla Luana Dinardo, Lucia Dias, Dalton de Alencar Fischer Chamone, Pedro Enrique Dorlhiac-Llacer, Frederico Luiz Dulley

Journal of Transplantation · 2009

DOI: 10.1155/2009/357093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Transplantation, 2009. Verfasst von Monika Conchon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Disciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, Brazil. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We describe the response of imatinib as lifesaving treatment of chronic myeloid leukemia (CML) relapse in seven patients who underwent allogeneic bone marrow transplantation (alloBMT) at our institution over a period of 4 years. Retrospective analysis of their medical records revealed that a mean age at transplant was 45.2 years. The median time to diagnosis was 7.4 years after transplant. At relapse, four, two, and one patients were classified as having hematologic, major molecular, and cytogenetic relapse, respectively. At imatinib initiation, five had CML in a chronic phase, while one patient was diagnosed as having accelerated phase and blast crisis. All these patients could be evaluated for the therapeutic efficacy. At a mean of follow-up of 1.9 years of therapy, all evaluable patients achieved major molecular response without compromising safety. Consistent with available data, our results indicate that imatinib is safe and effective treatment option for patients with relapse after BMT.

Autor:innen und Institutionen

  • Disciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, Brazil.

Zitieren

APA

Conchon, M., Sanabani, S. S., Bendit, I., Dinardo, C. L., Dias, L., Chamone, D. A., Dorlhiac-Llacer, P. E., & Dulley, F. L. (2009). The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation. Journal of Transplantation. https://doi.org/10.1155/2009/357093

Vancouver

Conchon M, Sanabani SS, Bendit I, Dinardo CL, Dias L, Chamone DA, et al. The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation. Journal of Transplantation. 2009. doi:10.1155/2009/357093

BibTeX
@article{Conchon2009,
  author = {Conchon, Monika and Sanabani, Sabri S and Bendit, Israel and Dinardo, Carla Luana and Dias, Lucia and Chamone, Dalton de Alencar Fischer and Dorlhiac-Llacer, Pedro Enrique and Dulley, Frederico Luiz},
  title = {The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation},
  journal = {Journal of Transplantation},
  year = {2009},
  doi = {10.1155/2009/357093}
}
Kostenlos starten →